Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.14 per share a year ago.